Gland Pharma Limited (NSE:GLAND)

Market Cap	302.54B +21.9%
Revenue (ttm)	61.13B +6.7%
Net Income	8.47B +20.3%
EPS	51.42 +20.3%
Shares Out	164.76M
PE Ratio	35.71
Forward PE	28.35
Dividend	18.00 (1.00%)
Ex-Dividend Date	Aug 14, 2025

Volume	45,127
Average Volume	280,294
Open	1,837.00
Previous Close	1,836.30
Day's Range	1,825.00 - 1,873.70
52-Week Range	1,277.80 - 2,131.00
Beta	0.41
RSI	55.50
Earnings Date	Jan 28, 2026

About Gland Pharma

Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neopla...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1978
• Employees: 4,351
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: GLAND

Financial Performance

In fiscal year 2025, Gland Pharma's revenue was 56.17 billion, a decrease of -0.85% compared to the previous year's 56.65 billion. Earnings were 6.99 billion, a decrease of -9.57%.